• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Allarity Therapeutics, Inc. - Common stock (NQ:ALLR)

    1.380 +0.050 (+3.76%)
    Streaming Delayed Price Updated: 10:18 AM EDT, Aug 26, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 8,875
    Open 1.360
    Bid (Size) 1.360 (100)
    Ask (Size) 1.400 (5,700)
    Prev. Close 1.330
    Today's Range 1.360 - 1.410
    52wk Range 0.7687 - 2.350
    Shares Outstanding 365,173,471
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +21.1%
    +21.1%
    1 Month
    +12.2%
    +12.2%
    3 Month
    -18.1%
    -18.1%
    6 Month
    +45.3%
    +45.3%
    1 Year
    +46.6%
    +46.6%

    More News

    Read More
    News headline image
    Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    Why Did Allarity Therapeutics Stock Double In Value Today? ↗
    Via Stocktwits
    News headline image
    Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Monday's Intraday Session ↗
    Via Benzinga
    News headline image
    Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    These stocks have an unusual volume in today's session ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Top stock movements in today's session. ↗
    Via Chartmill
    News headline image
    Check out the stocks that are attracting the most attention and driving market activity. ↗
    Via Chartmill
    News headline image
    Power Metallic’s (TSX-V: PNPN | OTCQB: PNPNF) Strategic Appointment Signals Major Paradigm Shift Ahead – More Stocks Inside
    Via AB Newswire
    Topics Government
    News headline image
    12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
    Via Benzinga

    Frequently Asked Questions

    Is Allarity Therapeutics, Inc. - Common stock publicly traded?
    Yes, Allarity Therapeutics, Inc. - Common stock is publicly traded.
    What exchange does Allarity Therapeutics, Inc. - Common stock trade on?
    Allarity Therapeutics, Inc. - Common stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Allarity Therapeutics, Inc. - Common stock?
    The ticker symbol for Allarity Therapeutics, Inc. - Common stock is ALLR on the Nasdaq Stock Market
    What is the current price of Allarity Therapeutics, Inc. - Common stock?
    The current price of Allarity Therapeutics, Inc. - Common stock is 1.380
    When was Allarity Therapeutics, Inc. - Common stock last traded?
    The last trade of Allarity Therapeutics, Inc. - Common stock was at 08/26/26 10:18 AM ET
    What is the market capitalization of Allarity Therapeutics, Inc. - Common stock?
    The market capitalization of Allarity Therapeutics, Inc. - Common stock is 503.94M
    How many shares of Allarity Therapeutics, Inc. - Common stock are outstanding?
    Allarity Therapeutics, Inc. - Common stock has 504M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.